紫杉醇和顺铂联合调强放疗治疗宫颈癌的临床疗效  

Clinical effect of paclitaxel and cisplatin combined with intensity modulated radiotherapy on treatment of cervical carcinoma

作　　者：李芷茹 曾守群[1] 李超[2] 罗莉[2] 黄叶才[3] LI Zhi-ru;ZENG Shou-qun;LI Chao;LUO Li;HUANG Ye-cai(Department of Oncoiogy,Chengdu Fifth People＇s Hospital,Sichuan Chengdu 611130,China;Department of Obstetrics and Gynecology,Chengdu Fifth People＇s Hospital,Sichuan Chengdu 610030,China;Department of Radiation Oncology,Sichuan Cancer Hospital,Sichuan Chengdu 610041,China)

机构地区：[1]成都市第五人民医院肿瘤科,四川成都610030 [2]成都市第五人民医院妇产科,四川成都610030 [3]四川省肿瘤医院放疗科,四川成都610041

出　　处：《中国妇幼健康研究》2018年第7期929-932,共4页Chinese Journal of Woman and Child Health Research

摘　　要：目的探讨紫杉醇和顺铂联合调强放疗治疗局部晚期宫颈癌的临床疗效。方法收集成都市第五人民医院、四川省肿瘤医院于2010至2015年收治的局部晚期初治年轻宫颈癌患者121例为研究对象,将其分为对照组和观察组。观察组患者60例,以顺铂为基础的同步放化疗(CCRT)后行紫杉醇和顺铂联合巩固性化疗2个周期;对照组患者61例,仅行顺铂为基础的同步放化疗。比较两组患者的近期治疗有效率、副反应发生率,及1年、2年生存率。结果在放疗结束后3个月,宫颈癌患者治疗的总有效率观察组和对照组分别为98.33%和93.44%,两组差异无统计学意义(P>0.05);副反应比较两组差异无统计学意义(P>0.05);1年生存率比较两组差异无统计学意义(P>0.05),2年生存率比较两组差异有统计学意义(χ~2=3.97,P=0.04<0.05)。结论同步放化疗后进行紫杉醇和顺铂联合巩固性化疗能够提高局部晚期宫颈癌患者的远期生存率。Objective To evaluate the clinical efficacy of cisplatin and paclitaxel combined with intensity modulated radiotherapy（IMRT）on the treatment of locally advanced cervical carcinoma.Methods Totally 121 patients with locally advanced cervical carcinoma,who were admitted in Chengdu Fifth People＇s Hospital and Sichuan Cancer Hospital from 2010 to 2015,were divided into control group and observation group.Sixty patients in the observation group accepted cisplatin-based concomitant chemoradiotherapy（CCRT）followed by paclitaxel and cisplatin to consolidate chemotherapy for 2 cycles,and 61 patients in the control group were treated with CCRT.The recent treatment efficiency,side effects and 1 year,2-year survival rate were compared.Results Three months after radiotherapy,the total effective rates of the observation group and the control group were98.33% and 93.44%,respectively,and the difference was not statistically significant（P〉0.05）.The side effects between two groups was not statistically significant（P〉0.05）.There was no significant difference in the 1-year survival rate between two groups（P〉0.05）,and the 2-year survival rate was significantly different（χ^2=3.97,P〈0.05）.Conclusion After CCRT,paclitaxel combined with cisplatin for consolidating chemotherapy can improve the long-term survival of patients with locally advanced cervical cancer.

关 键 词：紫杉醇 顺铂 调强放疗 局部晚期宫颈癌 同步放化疗 

分 类 号：R737.33[医药卫生—肿瘤]